Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 154
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,495
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Childhood obesity: public-health crisis, common sense cure
Ebbeling, C. B., Pawlak, D. B., & Ludwig, D. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09678-2 · Cited by 2,980
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O'Gara, P. T., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.007 · Cited by 2,257
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.021 · Cited by 1,702
Singh, J. P., Evans, J. C., Levy, D., Larson, M. G., Freed, L. A., Fuller, D. L., Lehman, B., & Benjamin, E. J. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)01064-9 · Cited by 1,339
Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
ACC/AHA guidelines for the management of patients with valvular heart disease
Bonow, R., Carabello, B., de Leon, A., Edmunds, L. H., Fedderly, B., Freed, M., Gaasch, W., McKay, C., Nishimura, R., O’Gara, P., et al. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00454-9 · Cited by 1,134
2006 WRITING COMMITTEE MEMBERS, Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.190748 · Cited by 1,114
Long-term maintenance of weight loss: Current status.
Jeffery, R. W., Epstein, L. H., Wilson, G. T., Drewnowski, A., Stunkard, A. J., & Wing, R. R. (2000) · Health Psychology · doi:10.1037/0278-6133.19.suppl1.5 · Cited by 1,093
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Kulke, M. H., & Mayer, R. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401107 · Cited by 741
Abel, E. D., Litwin, S. E., & Sweeney, G. (2008) · Physiological Reviews · doi:10.1152/physrev.00017.2007 · Cited by 736
Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000216787.85457.f3 · Cited by 727
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Sjöström, C. D., Lissner, L., Wedel, H., & Sjöström, L. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00436.x · Cited by 693
Putting chirality to work: the strategy of chiral switches
Agranat, I., Caner, H., & Caldwell, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd915 · Cited by 637
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)
Shimabukuro, T. T., Nguyen, M., Martin, D., & DeStefano, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.035 · Cited by 608
Anti-Obesity Drugs: A Review about Their Effects and Safety
Kang, J. G., & Park, C.-Y. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.13 · Cited by 593
Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561
Yanovski, S. Z., & Yanovski, J. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra012586 · Cited by 544
Primary pulmonary hypertension
Gaine, S. P., & Rubin, L. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02111-4 · Cited by 542
Leone, O., Veinot, J. P., Angelini, A., Baandrup, U. T., Basso, C., Berry, G., Bruneval, P., Burke, M., Butany, J., Calabrese, F., et al. (2012) · Cardiovascular Pathology · doi:10.1016/j.carpath.2011.10.001 · Cited by 535
Self-citationPulmonary Complications of Obesity
Koenig, S. M. (2001) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200104000-00006 · Cited by 530
Structural Basis for Molecular Recognition at Serotonin Receptors
Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X.-P., Vardy, E., et al. (2013) · Science · doi:10.1126/science.1232807 · Cited by 528
Eckel, R. H. (1997) · Circulation · doi:10.1161/01.cir.96.9.3248 · Cited by 513
Monoamine transporters and psychostimulant drugs
Rothman, R. B., & Baumann, M. H. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.054 · Cited by 502
Activation of Central Melanocortin Pathways by Fenfluramine
Heisler, L. K., Cowley, M. A., Tecott, L. H., Fan, W., Low, M. J., Smart, J. L., Rubinstein, M., Tatro, J. B., Marcus, J. N., Holstege, H., et al. (2002) · Science · doi:10.1126/science.1072327 · Cited by 491
Drugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479
Polypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
Impaired spatial and sequential learning in rats treated neonatally with d‐fenfluramine
Morford, L. L., Inman‐Wood, S. L., Gudelsky, G. A., Williams, M. T., & Vorhees, C. V. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02100.x · Cited by 455
“D-FEN was removed from the market in 1998 because of an association with valvulopathy (Connolly et al., 1997; Khan et al., 1998; Wee et al., 1998; Weissman et al., 1998).”
BackgroundEffects of Diet and Exercise on Obesity-Related Vascular Dysfunction in Children
Woo, K. S., Chook, P., Yu, C. W., Sung, R. Y. T., Qiao, M., Leung, S. S. F., Lam, C. W. K., Metreweli, C., & Celermajer, D. S. (2004) · Circulation · doi:10.1161/01.cir.0000126599.47470.be · Cited by 454
Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics
Murphy, D. L. (2004) · Molecular Interventions · doi:10.1124/mi.4.2.8 · Cited by 448
Nonsurgical Factors That Influence the Outcome of Bariatric Surgery: A Review
Hsu, L. K. G., Benotti, P. N., Dwyer, J., Roberts, S. B., Saltzman, E., Shikora, S., Rolls, B. J., & Rand, W. (1998) · Psychosomatic Medicine · doi:10.1097/00006842-199805000-00021 · Cited by 440
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
“These observations were histopathologically identical with the fibroplasia seen in carcinoid (with accompanying 5-HT-secreting tumors) or ergotamine-induced valve disease (Connolly et al., 1997; Kulke and Mayer, 1999).”
BackgroundResultMedicinal strategies in the treatment of obesity
Bray, G. A., & Tartaglia, L. A. (2000) · Nature · doi:10.1038/35007544 · Cited by 432
Anti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Schoen, F. J. (2008) · Circulation · doi:10.1161/circulationaha.108.805911 · Cited by 421
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Lipase Inhibitors for Obesity: A Review
Liu, T.-T., Liu, X.-T., Chen, Q.-X., & Shi, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110314 · Cited by 403
Thomsen, W. J., Grottick, A. J., Menzaghi, F., Reyes-Saldana, H., Espitia, S., Yuskin, D., Whelan, K., Martin, M., Morgan, M., Chen, W., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133348 · Cited by 402
“Other potential liabilities of agonist activity at human 5-HT2A or 5-HT2B receptors include cardiac valvular disease (Connolly et al., 1997; Devereux, 1998; Fitzgerald et al., 2000; Rothman et al., 2000; Horowski et al., 2004; Roth, 2007) and possibly pulmonary hypertension (Abenhaim et al.”
BackgroundCurrent pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Lagae, L., Sullivan, J., Knupp, K., Laux, L., Polster, T., Nikanorova, M., Devinsky, O., Cross, J. H., Guerrini, R., Talwar, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32500-0 · Cited by 384
Long-term pharmacotherapy for obesity and overweight
Padwal, R. S., Rucker, D., Li, S. K., Curioni, C., & Lau, D. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004094.pub2 · Cited by 384
Sibutramine Produces Dose‐Related Weight Loss
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., et al. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00701.x · Cited by 382
Structure and function of serotonin G protein-coupled receptors
McCorvy, J. D., & Roth, B. L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.009 · Cited by 372
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
The Evolution of Very‐Low‐Calorie Diets: An Update and Meta‐analysis
Tsai, A. G., & Wadden, T. A. (2006) · Obesity · doi:10.1038/oby.2006.146 · Cited by 371
Practice Guideline for the Treatment of Patients with Eating Disorders
Nakai, Y. (2016) · 心身医学 · Cited by 365
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
Rational Design of a Combination Medication for the Treatment of Obesity
Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D., et al. (2009) · Obesity · doi:10.1038/oby.2008.461 · Cited by 345
5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis
Xu, Y., Jones, J. E., Kohno, D., Williams, K. W., Lee, C. E., Choi, M. J., Anderson, J. G., Heisler, L. K., Zigman, J. M., Lowell, B. B., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.09.033 · Cited by 339
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Ng, A. C. T., Delgado, V., Borlaug, B. A., & Bax, J. J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00465-5 · Cited by 331
Current and Potential Drugs for Treatment of Obesity
Bray, G. A., & Greenway, F. L. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0383 · Cited by 331
Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs
Brewer, T., & Colditz, G. A. (1999) · JAMA · doi:10.1001/jama.281.9.824 · Cited by 327
Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene
Eddahibi, S., Hanoun, N., Lanfumey, L., Lesch, K. P., Raffestin, B., Hamon, M., & Adnot, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8678 · Cited by 325
Finer, N., James, W., Kopelman, P., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 325
Network of hypothalamic neurons that control appetite
Sohn, J.-W. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.4.272 · Cited by 321
The modern epidemiology of heart valve disease
Coffey, S., Cairns, B. J., & Iung, B. (2016) · Heart · doi:10.1136/heartjnl-2014-307020 · Cited by 321
Current status of medical and surgical therapy for obesity
Mun, E. C., Blackburn, G. L., & Matthews, J. B. (2001) · Gastroenterology · doi:10.1053/gast.2001.22430 · Cited by 310
5-Hydroxytryptamine receptors in the human cardiovascular system
Kaumann, A. J., & Levy, F. O. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.004 · Cited by 309
“Evidence for endothelium-dependent dilation of the perfused renal arterial bed of the rat by 5-HT, 5CT and 8-OH-DPAT in the presence of ritanserin (to block 5HT2A receptors) and tropisetron (to block 5-HT3 receptors) has been provided by Verbeuren et al. (1991). They showed that the agonist-mediated dilation was suppr…”
BackgroundSetola, V., Hufeisen, S. J., Grande-Allen, K. J., Vesely, I., Glennon, R. A., Blough, B., Rothman, R. B., & Roth, B. L. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1223 · Cited by 304
Body weight gain induced by antipsychotic drugs: mechanisms and management
Baptista, T. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb10908.x · Cited by 304
Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice
Vickers, S. P., Clifton, P. G., Dourish, C. T., & Tecott, L. H. (1999) · Psychopharmacology · doi:10.1007/s002130050952 · Cited by 291
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284
“…valvular disease has been described for agents used to treat obesity (fenfluramine and phentermine), Parkinson’s disease (ergot derivatives pergolide and cabergoline), and migraine (ergotamine and methysergide) (Connolly et al. 1997; Hauck et al. 1990; Schade et al. 2007; Zanettini et al. 2007).”
BackgroundNissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
A new cognitive behavioural approach to the treatment of obesity
Cooper, Z., & Fairburn, C. G. (2001) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(00)00065-6 · Cited by 272
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265
Khan, M. A., Herzog, C. A., St. Peter, J. V., Hartley, G. G., Madlon-Kay, R., Dick, C. D., Asinger, R. W., & Vessey, J. T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391101 · Cited by 265
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation
Jick, H., Vasilakis, C., Weinrauch, L. A., Meier, C. R., Jick, S. S., & Derby, L. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391102 · Cited by 263
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.6058 · Cited by 262
Al Suwaidi, J., Higano, S. T., Holmes, D. R., Lennon, R., & Lerman, A. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01212-8 · Cited by 258
Neel, J. V., Weder, A. B., & Julius, S. (1998) · Perspectives in Biology and Medicine · doi:10.1353/pbm.1998.0060 · Cited by 258
Long-Term Serotonin Administration Induces Heart Valve Disease in Rats
Gustafsson, B. I., Tømmerås, K., Nordrum, I., Loennechen, J. P., Brunsvik, A., Solligård, E., Fossmark, R., Bakke, I., Syversen, U., & Waldum, H. (2005) · Circulation · doi:10.1161/01.cir.0000159356.42064.48 · Cited by 257
Heart valve macro- and microstructure
Misfeld, M., & Sievers, H.-H. (2007) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2007.2125 · Cited by 254
Adverse Cardiovascular Events Temporally Associated With Ma Huang, an Herbal Source of Ephedrine
Samenuk, D., Link, M. S., Homoud, M. K., Contreras, R., Theohardes, T. C., Wang, P. J., & Estes, N. A. M. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.1.12 · Cited by 253
Losing Weight — An Ill-Fated New Year's Resolution
Kassirer, J. P., & Angell, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801013380109 · Cited by 248
Serotonin receptors and heart valve disease—It was meant 2B
Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.008 · Cited by 252
Neural Control of Energy Balance: Translating Circuits to Therapies
Gautron, L., Elmquist, J. K., & Williams, K. W. (2015) · Cell · doi:10.1016/j.cell.2015.02.023 · Cited by 234
COMPLICATIONS OF SURGERY FOR OBESITY
Byrne, T. K. (2001) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70190-0 · Cited by 248
Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists
Horvath, J., Fross, R. D., Kleiner‐Fisman, G., Lerch, R., Stalder, H., Liaudat, S., Raskoff, W. J., Flachsbart, K. D., Rakowski, H., Pache, J., et al. (2004) · Movement Disorders · doi:10.1002/mds.20201 · Cited by 243
Obesity: Overview of Prevalence, Etiology, and Treatment
Racette, S. B., Deusinger, S. S., & Deusinger, R. H. (2003) · Physical Therapy · doi:10.1093/ptj/83.3.276 · Cited by 238
The Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999) · JAMA · doi:10.1001/jama.281.18.1728 · Cited by 238
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides-Demos, L. L., Piccenna, L., & McNeil, J. J. (2011) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 243
MacLean, M. R., Herve, P., Eddahibi, S., & Adnot, S. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703570 · Cited by 232
“…in association or not with phentermine, has been shown recently to induce valvular heart disease very similar to those observed after exposure to 5-HT-like drugs such as ergotamine and methysergide, and with increased 5- HT levels associated with carcinoid disease (Connolly et al., 1997).”
ResultConvertible visceral fat as a therapeutic target to curb obesity
Giordano, A., Frontini, A., & Cinti, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.31 · Cited by 232
Murphy, D. L., Fox, M. A., Timpano, K. R., Moya, P. R., Ren-Patterson, R., Andrews, A. M., Holmes, A., Lesch, K.-P., & Wendland, J. R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.034 · Cited by 235
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis
Berglund, E. D., Liu, C., Sohn, J.-W., Liu, T., Kim, M. H., Lee, C. E., Vianna, C. R., Williams, K. W., Xu, Y., & Elmquist, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70338 · Cited by 229
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Bhattacharyya, S., Davar, J., Dreyfus, G., & Caplin, M. E. (2007) · Circulation · doi:10.1161/circulationaha.107.701367 · Cited by 224
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.